- Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
- Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
- Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
- Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
- Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
- Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
- Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
- Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
- Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
- Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
More ▼
Key statistics
On Tuesday, Citius Pharmaceuticals Inc (CTXR:NAQ) closed at 0.638, 6.33% above its 52-week low of 0.600, set on Feb 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.668 |
---|---|
High | 0.668 |
Low | 0.6307 |
Bid | 0.6252 |
Offer | 0.63 |
Previous close | 0.6654 |
Average volume | 3.71m |
---|---|
Shares outstanding | 180.67m |
Free float | 168.37m |
P/E (TTM) | -- |
Market cap | 126.02m USD |
EPS (TTM) | -0.2367 USD |
Data delayed at least 15 minutes, as of Jun 04 2024 21:00 BST.
More ▼